Mark Till
University of Texas Southwestern Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark Till.
Cellular Immunology | 1989
Jia Ling Li; Guo Liang Shen; Maria Ana Ghetie; Richard D. May; Mark Till; Victor Ghetie; Jonathan W. Uhr; George Janossy; Philip E. Thorpe; Peter Amlot; Ellen S. Vitetta
The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunoprecipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.
Journal of Immunological Methods | 1990
Victor Ghetie; Mark Till; Maria-Ana Ghetie; Jonathan W. Uhr; Ellen S. Vitetta
A method for the preparation and purification of large amounts (grams) of a conjugate containing recombinant CD4 antigen (rCD4) and chemically deglycosylated ricin A chain (dgA) is described. The cross-linking of rCD4 and dgA molecules was accomplished with N-succinimidyl-oxycarbonyl-alpha-methyl-(2-pyridyldithio)toluene (SMPT). The rCD4-dgA conjugate was purified by an automatic liquid chromatography system consisting of Blue-Sepharose CL-4B and Sephacryl S-200HR Pharmacia Bioprocess columns. The purified, endotoxin-free rCD4-dgA conjugate had a stable (hindered) disfulfide bond between rCD4 and dgA and was able to efficiently kill a human T cell line infected with HIV-1.
Science | 1987
Ellen S. Vitetta; Rj Fulton; Rd May; Mark Till; J W Uhr
Cancer Research | 1991
Ellen S. Vitetta; Marvin J. Stone; Peter Lloyd Amlot; Joseph W. Fay; Richard D. May; Mark Till; Joe Newman; Patty Clark; Robert D. Collins; David Cunningham; Victor Ghetie; Jonathan W. Uhr; Philip E. Thorpe
Cancer Research | 1988
Maria-Ana Ghetie; Richard D. May; Mark Till; Jonathan W. Uhr; Victor Ghetie; Phillip P. Knowles; Michele Relf; Alex Brown; Philip M. Wallace; George Janossy; Peter Amlot; Ellen S. Vitetta; Philip E. Thorpe
Science | 1988
Mark Till; Victor Ghetie; Timothy J. Gregory; Eric J. Patzer; James P. Porter; Jonathan W. Uhr; Daniel J. Capon; Ellen S. Vitetta
International Journal of Cancer | 1988
Guo-Liang Shen; Jia-Ling Li; Maria-Ana Ghetie; Victor Ghetie; Richard D. May; Mark Till; Alex N. F. Brown; Michele G. Relf; Phillip P. Knowles; Jonathan W. Uhr; George Janossy; Peter Amlot; Ellen S. Vitetta; Philip E. Thorpe
Cancer Research | 1988
Mark Till; Richard D. May; Jonathan W. Uhr; Philip E. Thorpe; Ellen S. Vitetta
Proceedings of the National Academy of Sciences of the United States of America | 1989
Mark Till; Zolla-Pazner S; M K Gorny; J S Patton; J W Uhr; Ellen S. Vitetta
Bioconjugate Chemistry | 1990
Victor Ghetie; Mark Till; Maria Ana Ghetie; Thomas F. Tucker; James P. Porter; Eric J. Patzer; James A. Richardson; Jonathan W. Uhr; Ellen S. Vitetta